D.E. Shaw & Co
AYTU icon

D.E. Shaw & Co’s AYTU BioPharma AYTU Stock Holding History

D.E. Shaw & Co’s Portfolio AYTU Stock Details AYTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-912
Closed -$13K – 5180
2022
Q2 		$13K Sell
912
-1,904
-68% -$24.4K ﹤0.01% 5094
2022
Q1 		$61K Sell
2,816
-2,666
-49% -$66.3K ﹤0.01% 5096
2021
Q4 		$148K Sell
5,482
-4,186
-43% -$181K ﹤0.01% 4971
2021
Q3 		$557K Buy
9,668
+4,872
+102% +$366K ﹤0.01% 4020
2021
Q2 		$480K Buy
+4,796
New +$563K ﹤0.01% 4057

Other funds holding AYTU

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

D.E. Shaw & Co's AYTU Position: Q3 2022 in Review

D.E. Shaw & Co sold out of AYTU BioPharma (AYTU) in Q3 2022, closing a stake of 912 shares — an estimated $13K sold.

D.E. Shaw & Co first reported a position in AYTU in Q2 2021 and held it in 5 quarters. The position peaked at $557K in Q3 2021. 42 funds tracked by Wall St. Rank hold AYTU as of Q3 2022.

  • D.E. Shaw & Co reported no remaining AYTU BioPharma position as of Q3 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 912 AYTU BioPharma shares in Q3 2022, an estimated $13K.
  • D.E. Shaw & Co first reported a position in AYTU BioPharma in Q2 2021 and held it in 5 quarters.
  • D.E. Shaw & Co's AYTU BioPharma position peaked at $557K in Q3 2021.
  • 42 funds tracked by Wall St. Rank held AYTU BioPharma as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.